CORE--HYBRIDOMA FACILITY

杂交岛核心设施将由大约30个UM-MAC使用 从事各种研究项目的调查人员，这些项目需要 单克隆抗体。杂交瘤设备(HF)是一项研究 实验室，其目的是产生体细胞杂交 (杂交瘤)产生所需特异性的单抗。它 由密歇根糖尿病研究和培训中心提供支持 (MDRTC)和密歇根大学多功能关节炎中心 (Um-MAC)，供这些中心内的调查人员使用，目前在 充值10%。它也被其他调查人员用来进行完全充电 基础。服务包括为小鼠接种疫苗，将B淋巴细胞与 骨髓瘤细胞建立杂交瘤、亚克隆和冷冻保存 杂交瘤、抗体同型和小鼠腹水的产生。 咨询可从杂交瘤核心董事的设计 确保有效检测的免疫策略和筛查试验 所需的单抗。产生的大多数杂交瘤 核心是小鼠起源，但大鼠、仓鼠和人类杂交瘤 也被制作出来了。自1980年成立以来，杂交瘤 Facility已经生产出了针对各种不同类型的 淋巴细胞表面抗原，肿瘤细胞抗原，纯化蛋白， 激素、激素受体和重组蛋白。在过去的四年里 多年的UM-MAC支持(1993-1996)进行了65次以上的融合 对于UM-MAC调查人员。进行了350多次亚克隆 在中国生产了杂交瘤和近400批单抗。 小鼠腹水。在此期间增加了各种专门的程序 目前的供资周期，以满足UM-MAC的各种需求 调查人员。 目前的建议将允许这一设施继续提供- UM-MAC实验室的最新杂交瘤技术。核心也将 为UM-MAC向量核心提供协作和咨询服务 协助可能希望选择重组抗体的调查人员- 就像噬菌体展示文库中的试剂。通过这些举措， 杂交瘤核心将保持在单抗的前沿 技术，并继续为UM-MAC提供最佳服务 调查人员。

The Hybridoma Core Facility will be used by approximately 30 UM-MAC investigators who are pursuing a variety of research projects that require monoclonal antibodies. The hybridoma Facility (HF) is a research laboratory, the purpose of which is to generate somatic-cell hybrids (hybridomas) that produce monoclonal antibodies of desired specificity. It is supported by the Michigan Diabetes Research and Training Center (MDRTC), and by the University of Michigan Multipurpose Arthritis Center (UM-MAC), for use by investigators within these centers, currently at a 10% recharge. It is also used by other investigators on a full recharge basis. Services include immunization of mice, fusion of B lymphocytes with myeloma cells to create hybridomas, subcloning and cryopreservation of hybridomas, antibody isotyping and production of ascites in mice. Consultation is available from the Hybridoma Core directors in design of immunization strategies and screening assays to ensure efficient detection of the desired monoclonal antibodies. The majority of hybridomas produced in the core are of murine origin, but rat, hamster and human hybridomas have also been produced. Since its establishment in 1980 the Hybridoma Facility has produced monoclonal antibodies against a wide variety of lymphocyte surface antigens, tumor cell antigens, purified proteins, hormones, hormone receptors and recombinant proteins. In the past four years of UM-MAC support (1993-1996) more than 65 fusions were performed for UM-MAC investigators. Subcloning was performed for more than 350 hybridomas and almost 400 monoclonal antibody batches were produced in murine ascites. A variety of specialized procedures have been added during the current funding cycle to address various needs of UM-MAC investigators. The current proposal will allow this facility to continue to provide up- to-date hybridoma technology for UM-MAC laboratories. The core will also provide collaborative and consultive services for the UM-MAC vector core in assisting investigators who may wish to select recombinant antibody- like reagents from phage display libraries. Through these initiatives, the Hybridoma Core will remain on the cutting edge of monoclonal antibody technology, and continue to provide optimal service to UM-MAC investigators.